CEL-SCI Corporation (CVM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on August 22, 2025, by CEL-SCI Corporation, a Colorado-based registrant. The filing addresses Item 8.01 (Other Events) regarding a strategic partnership and regulatory milestone in the Kingdom of Saudi Arabia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate development event rather than financial performance data.
Material Changes and Strategic Developments
- Regulatory Filing: A Breakthrough Medicine Designation application for Multikine (Leukocyte Interleukin, Injection) was filed with the Saudi Food and Drug Authority (SFDA).
- Commercial Partnership: CEL-SCI signed a Memorandum of Understanding (MOU) with Dallah Pharma, a subsidiary of Dallah Healthcare Company (Tadawul: 4004), for the commercialization of Multikine in Saudi Arabia.
- Timeline: A final partnership agreement is expected in the 3rd quarter of 2025. The SFDA response time for the designation is approximately 60 days.
- Market Access: Upon granting of the designation, Multikine would immediately become available for patient access, reimbursement, and sale in the region.
Outlook and Management Commentary
Management highlights that Dallah Pharma is well-positioned to procure reimbursement and accelerate the commercial launch of Multikine. Dallah Healthcare serves over three million patients annually through a network of hospitals, clinics, and home care services. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard regulatory timeline.
Investor Verification Checklist
- Confirm the status of the Breakthrough Medicine Designation application with the SFDA after the 60-day review period.
- Monitor the execution of the final partnership agreement between CEL-SCI and Dallah Pharma in Q3 2025.
- Verify the commercial launch timeline and reimbursement approval status in Saudi Arabia following the designation grant.
- Review subsequent filings for any financial impact or revenue recognition related to the Saudi Arabia partnership.